维普期刊资源整合服务平台（V6.5）

27篇 您的检索式：作者名="Bhuriya"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Favorable effects of vasodilators on left ventricular remodeling in asymptomatic patients with chronic moderate-severe aortic regurgitation and normal ejection fraction:a meta-analysis of clinical trials显示文摘	Shah RM Singh M Bhuriya R	2012	Clin Cardiol2012，35，10：	1
2	Newer anticoagulants as an alternate to warfarin in atrial fibrillation: achanglng paradigm显示文摘	Chaudhari D Bhuriya R Arora R	2011	Am J Ther2011，18，1：	1
3	Plasma Parathyroid Hormone level and prevalent Cardiovascular Disease in CKD Stages 3 and 4: An analysis from the kidney early evaluation program(KEEP)显示文摘	BHURIYA K LI S CHEN C S	2009	Am J Kidney Dis2009，53，4：	1
4	Fibromuscular dysplasia of the internal carotid circulation : an unusual presentation 显示文摘	Bhuriya R Arora R Khosla S	2008	Vasc Med2008，13，1：	1
5	Plasma prarthyroid hor- mone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP) 显示文摘	BHURIYA R LI S CHEN CS	2009	Am J Kidney Dis2009，53，4：	1
6	Dronedarone for atrial fibril - lation : a new therapeutic agent 显示文摘	Patel PD Bhuriya R Patel DD	2009	Vasc Health Risk Manag2009，5，18：	1
7	Plasma Parathyroid Hormone Level and Prevalent Cardiovascular Disease in CKD Stages 3 and 4: An Analysis From the Kidney Early Evaluation Program (KEEP)显示文摘	Rohit Bhuriya Suying Li Shu-Cheng Chen Peter A. McCullough George L. Bakris	2009	American Journal of Kidney Diseases2009，，4：	1
8	Plasma ParathyroidHormone Level and Prevalent Cardiovascular Disease inCKD Stages 3 and 4: An Analysis From the Kidney EarlyEvaluation Program (KEEP) 显示文摘	Bhuriya R Li S Chen CS	2009	Am J Kidney Dis2009，53，4：	1
9	Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4:an analysis from the Kidney Early Evaluation Program(KEEP)显示文摘	Bhuriya R Li S Chen SC	2009	Am J Kid Dis2009，53，4：	1
10	Dronedarone for atrial fibrilla- tion: a new therapeutic agent 显示文摘	Patel PD Bhuriya R Patel DD	2009	Vasc Health Risk Manag2009，5，：	1
11	Dronedarone for atrial fibrillation:a new therapeutic agent显示文摘	Patel PD Bhuriya R Patel DD	2009	Vase Health Risk Manag2009，5，：	1
12	Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4 an analysis from the Kidney Early Evaluation Program (KEEP) 显示文摘	Bhuriya R Li S Chen SC	2009	Am JKidneyDis2009，53，4：	1
13	Plasma parathyroid hor-mone level and prevalent cardiovascular disease in CKDstages 3 and 4:an analysis from the Kidney Early Evalua-tion Program(KEEP)显示文摘	Bhuriya R Li S Chen SC	2009	Am J Kidney Dis2009，53，44：	1
14	Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and recta-analysis显示文摘	Bhuriya R Singh M Molnar J	2010	Int J Cardiol2010，142，3：	1
15	Dronedarone for atrial fibrillation: a new therapeutic agent 显示文摘	PATEL PD BHURIYA R PATEL DD	2009	Vasc Health Risk Manag2009，5，：	1
16	Plasma parathyroid hormone lev- el and prevalent cardiovascular disease in CKD stages 3 and 4 : an analysis from the Kidney Early Evaluation Program (KEEP) 显示文摘	Bhuriya R Li S Chen SC	2009	Am J Kidney Dis2009，53，44：	1
17	Dronedarone for atrial fibrillation:a new therapeutic agent显示文摘	Patel PD Bhuriya R Patel DD	2009	Vasc Health Risk Manag2009，5，：	1
18	Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP) 显示文摘	Bhuriya R Li S Chen SC	2009	Am J Kidney Dis2009，53，44：	1
19	Dronedarone for atrial fibril-lation: a new therapeutic agent 显示文摘	Patel P D Bhuriya R Patel D D	2009	Vasc Health Risk Manag2009，5，18：	1
20	Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention:a meta-analysis of randomized trials显示文摘	Sethi A Bahekar A Bhuriya R	2012	Arch Cardiovasc Dis2012，105，11：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示